94 related articles for article (PubMed ID: 22724224)
1. [PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
Komiyama N
Nihon Rinsho; 2011 Nov; 69 Suppl 9():331-5. PubMed ID: 22724224
[No Abstract] [Full Text] [Related]
2. Pioglitazone vs glimepiride in the PERISCOPE trial.
Shah R
JAMA; 2008 Aug; 300(7):787-8; author reply 788. PubMed ID: 18714054
[No Abstract] [Full Text] [Related]
3. Pioglitazone vs glimepiride in the PERISCOPE trial.
Fresco C
JAMA; 2008 Aug; 300(7):787; author reply 788. PubMed ID: 18714055
[No Abstract] [Full Text] [Related]
4. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
5. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
6. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
7. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
Tseng CH; Huang TS
Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
[No Abstract] [Full Text] [Related]
8. Which should we ADOPT: sulphonylureas or glitazones?
Koshiyama H; Inagaki N; Seino Y
Diabet Med; 2007 Jul; 24(7):804. PubMed ID: 17596243
[No Abstract] [Full Text] [Related]
9. PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.
Cardiovasc J Afr; 2008; 19(3):159-62. PubMed ID: 18568180
[No Abstract] [Full Text] [Related]
10. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
11. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
[No Abstract] [Full Text] [Related]
12. Does PERISCOPE provide a new perspective on diabetic treatment?
Steg PG; Marre M
JAMA; 2008 Apr; 299(13):1603-4. PubMed ID: 18378632
[No Abstract] [Full Text] [Related]
13. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
14. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
15. [Evidences demonstrating the effects of prevention of major adverse cardiovascular events and anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive study and PERISCOPE study].
Kawamori R
Nihon Rinsho; 2011 Jan; 69 Suppl 1():671-7. PubMed ID: 21766679
[No Abstract] [Full Text] [Related]
16. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
17. Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
Hu YY; Ye SD; Zhao LL; Zheng M; Wu FZ; Chen Y
Clin Endocrinol (Oxf); 2010 Dec; 73(6):739-43. PubMed ID: 20874769
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic options: management strategies to optimize glycemic control.
Sisam DA
J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302
[No Abstract] [Full Text] [Related]
19. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
20. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
